• Poster on GNUV205 presented at the Immuno-Oncology Summit
• GNUV205 demonstrates Genuv’s “no-alpha/attenuated beta fused with anti-PD-1” strategy to reduce toxicity

Excerpt from the Press Release:

SEOUL, Republic of Korea & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Genuv Inc., a clinical-stage biotechnology company focused on innovative drug discovery for degenerative central nervous system diseases and advanced immuno-oncology therapeutics, unveiled a new drug candidate, GNUV205, a fusion of engineered IL2 and anti-PD-1 antibody that advances immuno-oncology science. The drug candidate, for unspecified solid tumors, shows powerful anti-tumor activity without the toxicity typically associated with current IL-2 treatments.

“We are excited by the promise shown by GNUV205,” said Sungho Han, Ph.D., founder and CEO of Genuv. “Treatments targeting IL-2 are uniquely powerful, but have typically been plagued by systemic toxicity issues. Our strategy using a ‘no-alpha but attenuated beta gamma’ IL-2 variant fused with a unique anti-PD-1 via Genuv’s proprietary hetero Fc technology shows stronger binding affinity in the tumor microenvironment compared to marketed treatments Proleukine®, Keytruda® and Opdivo® without Treg cell expansion.”

Jenny Choih, Ph.D., K.M.D., Genuv’s director of clinical development and president of its U.S. subsidiary, said, “The preclinical results we will be sharing at the Immuno-Oncology Summit demonstrate conclusively how our drug candidate GNUV205 overcomes the limitations seen with many immune checkpoint inhibitors as well as IL-2 treatment. Many patients become refractory and need additional treatment options. In addition, for many patients, treatment can be limited by the severe systemic toxicities associated with traditional IL-2 treatments.”

Click the button below to read the entire Press Release:

Continue Reading The Press Release